Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese …

C Zhou, YL Wu, X Liu, C Wang, G Chen, JF Feng… - 2012 - ascopubs.org
7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …
被引用次数：95 相关文章

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese …

C Zhou, YL Wu, X Liu, C Wang, G Chen… - Journal of Clinical …, 2012 - cir.nii.ac.jp
抄録< jats: p> 7520</jats: p>< jats: p> Background: The OPTIMAL study demonstrated
significant superiority for E versus GC in terms of progression-free survival (PFS), objective …